Evidence map›Paper›PMID 35870182›Full record

ArticleJournal of clinical laboratory analysis2022

Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer.

Yiming Shen, Zhengyu Wei, Chongchang Zhou, Jiangping Song, Jianing Wang, Jiada Wang, Linrong Wu, Shenzhe Fang, Zhisen Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFInternational journal of biological sciences · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yiming ShenDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Zhengyu WeiDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Chongchang ZhouDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0002-8728-6819
Jiangping SongDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Jianing WangDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Jiada WangDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Linrong WuDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.
Shenzhe FangMedical School of Ningbo University, Ningbo, China.
Zhisen ShenDepartment of Otolaryngology, Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0001-6660-0488
Ningbo University · CN

Funding

Medical and Health Research Project of Zhejiang Province 2019ZD018Medical and Health Research Project of Zhejiang Province 2021KY307Ningbo Health Branding Subject Fund PPXK2018-02Ningbo "Technology Innovation 2025" Major Special Project 2018B10015Ningbo "Technology Innovation 2025" Major Special Project 2020Z097Zhejiang Provincial Natural Science Foundation of China LQ21H130001Zhejiang Provincial Natural Science Foundation of China LY19H160014
6 · The paper itself

Abstract

backgroundSulfatase gene family members mediate various biological functions in tumor stroma and tumor cell environments. However, the expressions and prognostic value of Arylsulfatase I (ARSI), a sulfatase gene family member, in head and neck squamous cell carcinoma (HNSC) have not been fully established.

methodsArylsulfatase I expressions in pan-cancer were profiled using publicly available databases. Then, univariate Cox regression, Kaplan-Meier, and the Pearson's correlation analyses were performed to determine correlations between ARSI expressions and cancer prognosis, immune cell status, and drug sensitivity. Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were used to assess the potential mechanisms underlying ARSI functions in HNSC.

resultsArylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC. Elevated ARSI levels were associated with worse prognostic outcomes in HNSC patients. In addition, GSVA and GSEA showed that ARSI was highly involved in tumor cell escape and inflammatory responses. Expressions of ARSI negatively correlated with tumor mutation burden or microsatellite instability and positively correlated with immune-related genes. Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939.

conclusionArylsulfatase I is a promising prognostic and therapeutic target for HNSC.

Indexed as

Head and Neck NeoplasmsArylsulfatasesBiomarkers, TumorHumansPrognosisSquamous Cell Carcinoma of Head and NeckSulfatasesArylsulfatasesBiomarkers, TumorSulfatasesARSIdrug sensitivityGSEAGSVAHNSCprognosistumor microenvironment

Identifiers

PMID35870182
PMCPMC9459304
OpenAlexW4286771062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.